news
Johnson & Johnson’s COVID-19 vaccine safely elicits an immune response
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
List view / Grid view
Vaccines
news
UK vaccine supply chain workers to be offered COVID-19 jabs
Around 2,000 workers critical to the UK COVID-19 vaccine supply chain will be offered inoculations against the novel coronavirus.
news
Israel set to be first country to vaccinate entire population against COVID-19
A new report has said that Israel is expected to be the first country in the world to vaccinate its population against COVID-19.
news
Japan has pre-ordered COVID-19 vaccine doses for more than four times its population, says report
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
article
Cold chain in 2021: COVID-19’s continued influence
Dave Williams explores why the cold chain requirements for COVID-19 vaccines may have a lasting impact on the pharmaceutical supply chain.
news
Valneva may provide Europe with the only inactivated virus vaccine for COVID-19
The Europe Commission is currently in discussions to procure millions of doses of Valneva’s COVID-19 innactivated virus vaccine, VLA2001.
news
Biopharma industry commits to working with regulatory agencies on COVID-19 vaccines
A statement from biopharmaceutical industry groups has said they plan to work with regulatory agencies to gather data on COVID-19 vaccines.
webinar
Comparing EMA and Health Canada CTA submission for Phase I trials to US FDA IND application
13 January 2021 | By Altasciences
Watch this webinar on-demand which presents an overview of a foreign health authority’s requirements for gaining approval to conduct an FIH clinical trial by comparing Health Canada and European Medicines Agency (EMA) Clinical Trial Authorisation (CTA) processes to that of the FDA IND submission.
news
Pfizer COVID-19 vaccine set to generate sales of $30 billion
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
whitepaper
Whitepaper: Turbocharging Raman measurements
This whitepaper describes the proprietary HyperFlux™ optical spectrometer designs developed by Tornado Spectral Systems.
news
First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate
The trial will assess the safety and immunogenicity of a single intranasal dose of COVI-VAC in 48 healthy volunteers in the UK.
news
EMA receives authorisation application for AstraZeneca COVID-19 vaccine
The EMA has received a conditional marketing authorisation application for the Oxford-AstraZeneca COVID-19 vaccine.
news
Baxter BioPharma Solutions to manufacture Novavax’s COVID-19 vaccine
The agreement is expected to advance the commercial-scale manufacturing of the NVX-CoV2373 to enable it to be distributed across Europe following regulatory approval.
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-300x278.jpg)
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-scaled-e1607955047519.jpg)
article
Pfizer-BioNTech COVID-19 vaccine is effective against new, highly transmissible COVID-19 strains, finds study
Research shows that the antibodies induced by the Pfizer-BioNTech COVID-19 vaccine can neutralise SARS-CoV-2 viruses with the N501Y mutation.
news
UK’s MHRA approves Moderna’s COVID-19 vaccine
The MHRA has given the green light to the Moderna COVID-19 vaccine for use in the UK, making it the third to be approved in the country.
